We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

Spreading its geographic wings further, in the face of ongoing difficulties in China, UK pharma major AstraZeneca has ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms ...

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.